Allen, T. M. and Cullis, P. R. 2013. Liposomal drug
delivery systems: from concept to clinical
applications. Advanced Drug Delivery Reviews. Vol 65, No. 1: 36-48.
Auguste, D, Furman, K, Won, A Fuller, J, Armes, S, Deming, T and Langer, R. 2008. Triggered release of siRNA from poly(ethylene glycol)-protected, pH-dependent liposomes. Journal of Controlled Release. Vol. 130:266-27
Bartlett, H. and Eperjesi, F. 2004. An ideal ocular nutritional supplement? Ophthalmic and Physiological Optics. Vol 24, No. 4: 339-349.
Buyens, K, Smedt, S, Braekmans, K, Demeester, J, Peeters, L, van Grunven, L, Jeu, X, Sawant, R, Torchilin, V, Fakasova, K Orgis, M and Sanders, N. 2012. Liposome based systems for systemic siRNA delivery: Stability in blood sets the requirements for optimal carrier design. Journal of Controlled Release. Vol 158: 362-370.
Lian, T. and Ho, R.J. 2001. Trends and developments in lioposomal delivery systems. Journal of Pharmaceutical Sciences. Vol 90, No. 6: 667-680.
Liu, Z., Ma, X., Deng, B., Huang, Y., Bo, R., Gao, Z., Yu,Y., Hu,Y., We, Y., and Wang, D. 2015. Development of liposomal Ganoderma lucidum polysaccharide: formulation optimization and evaluation of its immunological activity. Carbohydrate Polymers. Vol 117: 510-517.
N.A. "How to Make Your Own Liposomal Vitamin C." 2014. EMR Labs, LLC. Retrieved April 22, 2015 from <https://www.quantumbalancing.com/liposomalC.htm>
N. A. “DepoCyt(e)®.” 2015. Pacira. Retrieved April 21, 2015 from < http://www.pacira.com/products/depocyt.php>
N. A. “RX ONLY DEPOCYT®.” 2000. U.S. Food and Drug Administration. Retrieved April 21, 2015 from < http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021041s018lbl.pdf>
Phuphanich,S., Maria, B., Braeckman, R., and Chamberlain, M. 2007. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt®) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. Journal of Neuro-Oncology. Vol 81, No. 2: 201-208.
Shoji, Y. and Nakashima, H. 2004. Nutraceutics and delivery systems. Journal of Drug Targeting. Vol 12, No 6: 385-391.
Singh, A. K. and Das, J. 1998. Liposome encapsulated vitamin A compounds exhibit greater stability and diminished toxicity. Biophysical Chemistry. Vol 73, No. 1: 155-162.
Templeton, N.S., Lasic, D.D., Frederik, P.M., Strey, H.H., Roberts, D.D., and Pavlakis, G.N. 1997. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nature Biotechnology. Vol 15: 647-642.
Tahover, E., Patil, Y., and Gabison A. 2014. Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes. Anti-Cancer Drugs. Vol 26, No. 3: 241-258.
Waknine, Y. “FDA Approvals: Kadian, Depocyt, Reclast.” 2007. Medscape. Retrieved April 21, 2015 from <http://www.medscape.com/viewarticle/558084>
Schiffelers RM, Ansari A, Xu J, et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 2004;32(19):e149.
Lee J.M., Yoon, T.J., and Cho, Y.S. 2013. Recent developments in nanoparticle-based siRNA delivery for cancer therapy. Biomed Res Int. 2013;2013:782041.
Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009;136(4):642-55.
http://pilladvised.com/wp-content/uploads/2011/04/risks-benefits.jpg
http://lowres.jantoo.com/medical-lab_rats-rats-scientist-vaccines-labs-08336714_low.jpg
applications. Advanced Drug Delivery Reviews. Vol 65, No. 1: 36-48.
Auguste, D, Furman, K, Won, A Fuller, J, Armes, S, Deming, T and Langer, R. 2008. Triggered release of siRNA from poly(ethylene glycol)-protected, pH-dependent liposomes. Journal of Controlled Release. Vol. 130:266-27
Bartlett, H. and Eperjesi, F. 2004. An ideal ocular nutritional supplement? Ophthalmic and Physiological Optics. Vol 24, No. 4: 339-349.
Buyens, K, Smedt, S, Braekmans, K, Demeester, J, Peeters, L, van Grunven, L, Jeu, X, Sawant, R, Torchilin, V, Fakasova, K Orgis, M and Sanders, N. 2012. Liposome based systems for systemic siRNA delivery: Stability in blood sets the requirements for optimal carrier design. Journal of Controlled Release. Vol 158: 362-370.
Lian, T. and Ho, R.J. 2001. Trends and developments in lioposomal delivery systems. Journal of Pharmaceutical Sciences. Vol 90, No. 6: 667-680.
Liu, Z., Ma, X., Deng, B., Huang, Y., Bo, R., Gao, Z., Yu,Y., Hu,Y., We, Y., and Wang, D. 2015. Development of liposomal Ganoderma lucidum polysaccharide: formulation optimization and evaluation of its immunological activity. Carbohydrate Polymers. Vol 117: 510-517.
N.A. "How to Make Your Own Liposomal Vitamin C." 2014. EMR Labs, LLC. Retrieved April 22, 2015 from <https://www.quantumbalancing.com/liposomalC.htm>
N. A. “DepoCyt(e)®.” 2015. Pacira. Retrieved April 21, 2015 from < http://www.pacira.com/products/depocyt.php>
N. A. “RX ONLY DEPOCYT®.” 2000. U.S. Food and Drug Administration. Retrieved April 21, 2015 from < http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021041s018lbl.pdf>
Phuphanich,S., Maria, B., Braeckman, R., and Chamberlain, M. 2007. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt®) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. Journal of Neuro-Oncology. Vol 81, No. 2: 201-208.
Shoji, Y. and Nakashima, H. 2004. Nutraceutics and delivery systems. Journal of Drug Targeting. Vol 12, No 6: 385-391.
Singh, A. K. and Das, J. 1998. Liposome encapsulated vitamin A compounds exhibit greater stability and diminished toxicity. Biophysical Chemistry. Vol 73, No. 1: 155-162.
Templeton, N.S., Lasic, D.D., Frederik, P.M., Strey, H.H., Roberts, D.D., and Pavlakis, G.N. 1997. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nature Biotechnology. Vol 15: 647-642.
Tahover, E., Patil, Y., and Gabison A. 2014. Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes. Anti-Cancer Drugs. Vol 26, No. 3: 241-258.
Waknine, Y. “FDA Approvals: Kadian, Depocyt, Reclast.” 2007. Medscape. Retrieved April 21, 2015 from <http://www.medscape.com/viewarticle/558084>
Schiffelers RM, Ansari A, Xu J, et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 2004;32(19):e149.
Lee J.M., Yoon, T.J., and Cho, Y.S. 2013. Recent developments in nanoparticle-based siRNA delivery for cancer therapy. Biomed Res Int. 2013;2013:782041.
Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009;136(4):642-55.
http://pilladvised.com/wp-content/uploads/2011/04/risks-benefits.jpg
http://lowres.jantoo.com/medical-lab_rats-rats-scientist-vaccines-labs-08336714_low.jpg